These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12565092)

  • 1. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban.
    Schneider DJ; Herrmann HC; Lakkis N; Aguirre F; Lo MW; Yin KC; Aggarwal A; Kabbani SS; DiBattiste PM
    Am J Cardiol; 2003 Feb; 91(3):334-6. PubMed ID: 12565092
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban.
    Schneider DJ; Herrmann HC; Lakkis N; Aguirre F; Wan Y; Aggarwal A; Kabbani SS; DiBattiste PM
    Am J Cardiol; 2002 Dec; 90(12):1421-3. PubMed ID: 12480064
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions.
    Kabbani SS; Aggarwal A; Terrien EF; DiBattiste PM; Sobel BE; Schneider DJ
    Am J Cardiol; 2002 Mar; 89(5):647-50. PubMed ID: 11867064
    [No Abstract]   [Full Text] [Related]  

  • 5. Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention.
    Siotia A; Buckland R; Judge HM; Sastry P; Storey RF
    Thromb Haemost; 2006 Jun; 95(6):997-1002. PubMed ID: 16732379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris.
    Soffer D; Moussa I; Karatepe M; Harjai KJ; Boura J; Dixon SR; Grines CL; O'Neill WW; Roubin GS; Moses JW
    Am J Cardiol; 2003 Apr; 91(7):872-5. PubMed ID: 12667576
    [No Abstract]   [Full Text] [Related]  

  • 7. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE
    Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract]   [Full Text] [Related]  

  • 8. Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
    Mansur Ade P; Roggerio A; Takada JY; Caribé PM; Avakian SD; Strunz CM
    Sao Paulo Med J; 2016 Jan; 134(3):199-204. PubMed ID: 26786608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
    Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tirofiban counteracts pending myocardial infarction.
    Rasmanis G; Sylvén C
    J Intern Med; 2000 Oct; 248(4):349-52. PubMed ID: 11086647
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement.
    Danzi GB; Capuano C; Sesana M; Baglini R
    Catheter Cardiovasc Interv; 2004 Feb; 61(2):179-84. PubMed ID: 14755808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The glycoprotein IIb/IIIa platelet receptor blocker tirofiban, but not heparin, counteracts platelet aggregation in unstable angina pectoris.
    Mattsson E; Martinsson A; Nyqvist O; Rasmanis G; Sylvén C; Karlberg KE
    Am J Cardiol; 1997 Oct; 80(7):938-40. PubMed ID: 9382012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tirofiban. A review of its use in acute coronary syndromes.
    McClellan KJ; Goa KL
    Drugs; 1998 Dec; 56(6):1067-80. PubMed ID: 9878994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of inhaled nitric oxide and tirofiban for acute coronary syndromes: a report from the cardiovascular and renal advisory panel of the food and drug administration.
    Lindenfeld J
    Circulation; 1998 Nov; 98(18):1829-30. PubMed ID: 9799198
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
    Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
    Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited.
    Lakkis N; Lakiss N; Bobek J; Farmer J
    Catheter Cardiovasc Interv; 2002 Aug; 56(4):474-7. PubMed ID: 12124955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two i.v. antiplatelet agents marketed for coronary disease.
    Am J Health Syst Pharm; 1998 Jul; 55(14):1440, 1443. PubMed ID: 9676283
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of early high-loading-dose tirofiban on platelet activity in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention].
    Ren XN; Wang LF; Wang MS; Xu L
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Feb; 40(2):131-5. PubMed ID: 22490713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
    Saltzman AJ; Mehran R; Hooper WC; Moses JW; Weisz G; Collins MB; Lansky AJ; Kreps EM; Leon MB; Stone GW; Dangas G
    J Invasive Cardiol; 2010 Jan; 22(1):2-6. PubMed ID: 20048389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M; Tebaldi M; Campo G; Gambetti S; Bristot L; Monti M; Parrinello G; Ferrari R;
    JACC Cardiovasc Interv; 2012 Mar; 5(3):268-77. PubMed ID: 22440491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.